secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHEMED CORP (CHE)
CIK:        0000019584
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001562762-25-000032
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemed Q4 2024 revenue up 9.2% to $640M; adj. EPS $6.83; guides FY2025 adj. EPS $24.95-$25.45
--------------------------------------------------------------------------------

- GAAP diluted EPS $6.02 (+2.0% YoY); adjusted diluted EPS $6.83 (+3.5% YoY).
- VITAS net patient revenue $411M (+17.4% YoY); ADC 22,179 (+14.6%).
- Roto-Rooter revenue $229M (-2.9% YoY); adjusted EBITDA margin 26.3% (-120 bps).
- FY2025 guidance: VITAS revenue growth 10.5%-11.3%, Roto-Rooter revenue growth 2.4%-3.0%.
- No debt; $178.4M cash; repurchased 388,235 shares for $212.8M at $548.13/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/19584/000156276225000032/0001562762-25-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/19584/000156276225000032/che-20250226x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-25-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer